Monjuvi(Tafasitamab-Cxix)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$1.0M
Medicare cost, 2024
$1.0M
Medicare cost, 2024
Medicare drug plans spent $1.0 million on Monjuvi (tafasitamab-cxix) in 2024, for 75 prescriptions and refills filled by 14 patients. It was first approved in 2020. At about $13,816 per prescription it is a high-cost drug.
Medicare cost, 2024
$1.0M
-8.2% from 2023
Prescriptions
75
$13,816.31 per claim
Patients
14
15 prescribers
Total spending, 2024
$1.0M
$74,015.95 per patient
Questions and answers
How much does Medicare spend on Monjuvi?
Medicare prescription drug plans paid $1.0M for Monjuvi in 2024, for 75 prescriptions and refills to 14 patients (down 8.2% from 2023). The average cost per claim was $13,816.31.
Which state spends the most on Monjuvi?
Pennsylvania had the highest Medicare cost for Monjuvi in 2024: $179K for 24 claims, followed by Arizona ($129K).
Who prescribes Monjuvi the most?
John D Sprandio Jr., hematology-oncology in Broomall, PA, had the highest Medicare cost for Monjuvi in 2024: 24 claims costing $179K.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Monjuvi was $1.0M in 2024, after a high of $1.2M in 2023.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Monjuvi, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| John D Sprandio Jr. Broomall, PA | Hematology-Oncology | 24 | Under 11 | $179K |
| Timothy E Mathews Phoenix, AZ | Nurse Practitioner | 12 | Under 11 | $67K |
| Donald W Northfelt Phoenix, AZ | Hematology-Oncology | 11 | Under 11 | $62K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 4 | 20 | - | $313K |
| 2023 | 16 | 67 | 15 | $1.1M |
| 2024 | 15 | 75 | 14 | $1.0M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Morphosys/Incyt | 75 | $1.0M |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 2
- RxNorm concept IDs
- 2387338, 2387343
- Application numbers
- BLA761163
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 906 side-effect reports named tafasitamab-cxix, the active ingredient of Monjuvi (reports from 2020 on). 665 of them (73.4%) were serious, 131 named a death and 144 named a hospital stay. The reactions named most often were disease progression, off label use and lymphoma. 801 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
906
65 in 2025 (-51.9% from 2024)
Serious
73.4%
665 reports
Deaths named
131
14.5% of reports
Hospital stays
144
15.9% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Monjuvi?
906 reports from 2020 through September 2026 named tafasitamab-cxix, the active ingredient of Monjuvi. 665 of them (73.4%) were serious, 131 named a death and 144 named a hospital stay.
What are the most reported side effects of Monjuvi?
239 reports named disease progression, the reaction named most often, followed by off label use (168) and lymphoma (165). In the last 5 years the reaction named most often was disease progression (214 reports). A report can name several reactions.
How many side-effect reports named Monjuvi in 2025?
65 reports were received in 2025 (-51.9% from 2024). 2026 so far: 42 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Monjuvi caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Monjuvi caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Drug approvals (1 approval on file for tafasitamab-cxix) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (tafasitamab-cxix) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.